MedWatch

Aspiring nicotine company’s share goes right to the top. Next stop: the US

Though Enorama Pharma has not one single nicotine gum yet, its share price increased by 1600 percent in four months. Moreover, the the Swedish company is facing a breakthrough in the US and aiming for the Asian market, says Danish Deputy Managing Director.

Foto: Enorama Pharma

October 12, 2017, is most likely a memorable day for Anette Agerskov, Deputy Managing Director in Enorama Pharma.

For nine months, she had negotiated with the Indian pharma group Dr. Reddy's Laboratories on a deal that would bring her small company into a whole new league. And on October 12, she had it in writing: Dr. Reddy's Laboratories agreed to market and sell Enorama Pharma’s nicotine gum on the biggest of all markets – the US.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

EU-lande blåstempler nye beføjelser til agentur

Det europæiske center for sygdomsforebyggelse og -kontrol, ECDC, får nu nye muskler til kontrol og netværksopbygning i kampen mod fremtidens epidemier. ”Dagens aftale er lig med state-of-the-art overvågning,” siger EU-topfolk.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier